

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/23, A61P 9/10	A1	(11) International Publication Number: WO 00/48592 (43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/EP00/00957 (22) International Filing Date: 7 February 2000 (07.02.00) (30) Priority Data: MI99A000313 17 February 1999 (17.02.99) IT (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT). (72) Inventor; and (75) Inventor/Applicant (for US only): PAMPARANA, Franco [IT/IT]; Piazza Firenze, 19, I-20100 Milano (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS (57) Abstract The invention concerns the use of essential fatty acids with a high content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) or a high concentration mixture thereof in the preparation of a medicament useful for preventing mortality, in particular due to sudden death, in patients who have suffered from a myocardial infarction.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

"ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS"

DESCRIPTION

This invention concerns the use of a pharmaceutical composition containing
5 essential fatty acid ethyl esters originating from fish oils, in
particular as a high concentration mixture of ethyl esters of (20:5 ω 3)
eicosapentaenoic acid (EPA) and (22:6 ω 3) docosahexaenoic acid (DHA) in
the prevention of cardiovascular events, especially of mortality in
patients who have survived the hospitalization phase of acute myocardial
10 infarction (AMI).

It is well known that certain essential fatty acids contained in fish oil
have a therapeutic effect in the prevention and treatment of
cardiovascular disorders, such as in the treatment of thrombosis,
hypercholesterolemia, arteriosclerosis, cerebral infarction and
15 hyperlipemias.

U.S. Patents US 5,502,077, US 5,656,667 and US 5,698,594 can be quoted as
examples.

From the above prior art, it is known in particular the utility of fatty
acids belonging to the ω -3 family, more specifically (20:5 ω 3)
20 eicosapentaenoic acid (EPA) and (22:6 ω 3) docosahexaenoic acid (DHA) in
treating the above-mentioned disorders.

Indeed EPA, being a precursor of PGI₃ and TxA₃, exerts a preventing
platelet aggregation effect and an antithrombotic effect that can be
ascribed to inhibition of cyclooxygenase (similar effect to that of
25 aspirin) and/or to competition with arachidonic acid for this enzyme, with
consequent reduction in the synthesis of PGE₂ and TxA₂, which are well
known platelet aggregating agents.

On the other hand DHA is the most important component of cerebral lipids
in man and furthermore, being a structural component of the platelet cell,

it intervenes indirectly in increasing platelet fluidity, thus playing an important role in antithrombotic activity.

International patent application W089/11521, whose description is herein incorporated by reference, describes in particular an industrial process
5 for extracting mixtures with a high content in poly-unsaturated acids, including EPA and DHA and their ethyl esters, from animal and/or vegetable oils.

Mixtures of fatty acids, especially EPA/DHA, obtained according to W089/11521, are reported to be particularly useful in the treatment of
10 cardiovascular diseases.

However, currently used treatments in human therapy have been shown to be insufficient in preventing cardiovascular events, and more specifically mortality, in particular due to sudden death, which happen in patients who have had a myocardial infarction, on account of recurrences after a first
15 acute myocardial infarction episode.

Therefore, there still is the need for an effective drug, in particular for preventing these recurrences.

Object of this invention, therefore, is the use of essential fatty acids with a high content in EPA-ethyl ester or DHA-ethyl ester or a high
20 concentration mixture thereof, in the preparation of a medicament useful for preventing mortality, due, for instance, to cardiovascular events or sudden death, in patients who have suffered from a myocardial infarction.

According to a preferred aspect this invention therefore provides the use of essential fatty acids with a high content in EPA-ethyl ester or DHA-ethyl ester or a high concentration mixture thereof, in the preparation of
25 a medicament useful for preventing sudden death in patients who have suffered from a myocardial infarction.

For ease of description "EPA-ethyl ester" and "DHA-ethyl ester" will be also quoted here as "EPA" and "DHA".

30 An essential fatty acid with high content in EPA-ethyl ester or DHA-ethyl

ester, according to the present invention, preferably contains more than 25% by weight (b.w.), in particular from about 60 to about 100% of such ester.

These compounds can be obtained by known methods.

- 5 In an essential fatty acid with a high concentration mixture of EPA-ethyl ester and DHA-ethyl ester, preferably such mixture has a content in EPA + DHA greater than 25% by weight, in particular from about 30 to about 100% by weight, preferably about 85% by weight.

In the EPA/DHA mixture, EPA preferably is present in a percentage from
10 about 40 to about 60% by weight and DHA, preferably in a percentage from about 25 to about 45-50%.

In any case the preferred EPA/DHA ratio in such EPA/DHA mixture is about 0.9/1.5.

15 PHARMACOLOGY

The efficacy of the treatment, according to the invention, is, for instance, proven by the fact that a surprising and highly significant reduction in post-infarction mortality was observed by such treatment in a clinical trial that lasted for 3.5 years, with protocols substantially
20 designed as follows:

- 1 a "control " group received the standard therapy which is usually given to infarcted patients;
- 2 a "treatment" group, besides the therapy that was given to the "control" group, received 85% EPA+DHA (1 g daily);
- 25 3 a "treatment" group, besides the therapy that was given to the "control" group received vitamin E; and
- 4 a "treatment" group, besides the therapy that was given to the control group, received vitamin E and 85% EPA+DHA (1 g daily).

In fact the group of patient "treated" according to protocol 2 showed, in
30 comparison to "control" group 1, a decrease of about 20% in total

mortality, with a decrease of about 40% of mortality due to sudden death and a notable reduction in mortality due to other cardiovascular events.

On the contrary, no significant results were achieved in group 3 as compared to the control group 1, whereas there was a reduction in total
5 mortality of about 19% in group 4 as compared to the control group, with results that were similar to those obtained in treated group 2. From the above clinical results, the person skilled in the art will appreciate that, the use of a pharmaceutical composition in accordance to the present invention is certainly useful in human therapy in preventing mortality in
10 patients who have suffered from a myocardial infarction.

Accordingly, this invention provides a method for preventing mortality in a patient who has survived a myocardial infarction, comprising administering to such patient a therapeutically effective amount of a medicament containing essential fatty acids with a high content in EPA-
15 ethyl ester or DHA-ethyl ester or a high concentration mixture thereof.

As known, sudden death is an important contributor to the mortality rate in patients with cardiac disease, accounting for over 450,000 death per year in the USA.

About 80% of such patients, particularly those survivors of acute
20 myocardial infarction with low ventricular ejection fractions, are at high risk of sudden death or reinfarction.

The above clinical results show that the present invention provides a new and valuable therapeutic tool for preventing sudden death in patients in particular in those who survived acute myocardial infarction.

25 Accordingly, as a preferred aspect, the present invention also provides a method for preventing sudden death in a patient, who is survivor of myocardial infarction, comprising administering to such patient a therapeutically effective amount of a medicament containing essential fatty acids with a high content in EPA-ethyl ester or DHA-ethyl ester or a
30 high concentration mixture thereof.

The essential fatty acids, according to the invention, can either have a high content, for instance more than 25% b.w., in EPA-ethyl ester or DHA-ethyl ester or in a mixture thereof. However EPA-ethyl ester and DHA-ethyl ester are preferably present as a mixture thereof with a content in
5 EPA+DHA higher than 25% b.w, in particular from about 30 to about 100% b.w., preferably about 85% b.w.

Based on the obtained clinical results, according to a preferred aspect of the invention, the dosage of an essential fatty acid containing a EPA+DHA mixture with 85% b.w. titer for oral administration to a patient may vary
10 from about 0.7 g to about 1.5 g daily, preferably about 1 g daily.

This amount of product as EPA+DHA mixture (or amount of EPA-ethyl ester alone or DHA-ethyl ester alone) may be administered in several divided doses throughout the day or preferably in a single administration, in order to achieve the desired hematic level. Obviously it is at the
15 discretion of the physician to adjust the quantity of product to be administered according to the age, weight and general conditions of the patient.

The medicament, e.g. in the form of a pharmaceutical composition, according to this invention can be prepared according to known methods in
20 the art. The preferred route of administration is the oral one, however leaving alternative routes of administration, such as the parenteral route, to the discretion of the physician.

The following examples illustrate preferred formulations for oral administration, but do not intend to limit the invention in any way.

25 Gelatin capsules

According to known pharmaceutical techniques, capsules having the composition below and containing 1 g of active ingredient (EPA + DHA, 85% titer) per capsule are prepared.

30 Formulation 1

	EPA-ethyl ester	525 mg/capsule;
	DHA-ethyl ester	315 mg/capsule;
	d-alpha tocopherol	4 IU/capsule;
	gelatin	246 mg/capsule
5	glycerol	118 mg/capsule;
	red iron oxide	2.27 mg/capsule;
	yellow iron oxide	1.27 mg/capsule

Formulation 2

10	Ethyl esters of poly- unsaturated fatty acids	1000 mg
	with content in ethyl esters of ω -3 poly-unsaturated esters (eicosapentaenoic EPA ,	
15	docosahexaenoic (DHA)	850 mg
	d-1- α tocopherol	0.3 mg
	gelatin succinate	233 mg
	glycerol	67 mg
	sodium p-oxybenzoate	1.09 mg
20	sodium propyl p-oxobenzoate	0.54 mg

CLAIMS

1. Use of essential fatty acids containing a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) in the preparation of a medicament useful for preventing mortality in a patient who has suffered from a myocardial infarction where the content in EPA+DHA in such mixture is greater than 25% b.w.
2. Use according to claim 1, wherein the medicament is useful for preventing mortality due to sudden death in a patient who has suffered from a myocardial infarction.
3. Use according to claim 1 or 2, wherein the content in EPA+DHA in such mixture is from about 30 to about 100% b.w.
4. Use according to claim 1 or 2, wherein the content in EPA+DHA in such mixture is about 85% b.w.
5. Use according to anyone of claims 1 to 4, wherein the medicament is for oral administration.
6. Use according to claim 4, wherein the medicament is for oral administration, at a dosage from about 0.7 g to about 1.5 g daily.
7. Use according to claim 6, wherein the EPA/DHA ration in the EPA+DHA mixture is about 0.9/1.5.
8. Use of essential fatty acids containing eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) in the preparation of a medicament useful for preventing mortality in a patient who has suffered from a myocardial infarction, wherein the EPA or DHA content is greater than 25% b.w.
9. Use according to claim 8, wherein the medicament is useful for preventing mortality due to sudden death in a patient who has suffered from a myocardial infarction.
10. Use according to claim 8 or 9, wherein the EPA or DHA content is from about 60 to about 100% b.w.
11. Use according to anyone of claims 8 to 10, wherein the medicament is

for oral administration.

12. A method for preventing mortality in a patient who has survived a myocardial infarction, comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) wherein the content in EPA+DHA in such mixture is greater than 25% b.w.
13. A method according to claim 12, wherein the content in EPA+DHA in such mixture is from about 30 to about 100% b.w.
14. A method according to claim 12, wherein the content in EPA+DHA in such mixture is about 85% b.w.
15. A method according to claim 12, 13 or 14, wherein the medicament is administered orally.
16. A method according to claim 14, wherein the medicament is administered orally at a dosage from about 0.7g to about 1.5 g daily.
17. A method according to claim 16, wherein the EPA/DHA ratio in the EPA+DHA mixture is about 0.9/1.5
18. A method for preventing sudden death in a patient, who is survivor of myocardial infarction, comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), wherein the content in EPA+DHA in such mixture is greater than 25% b.w.
19. A method according to claim 18, wherein the content in EPA+DHA in such mixture is from about 30 to about 100% b.w.
20. A method according to claim 18, wherein the content in EPA+DHA in such mixture is about 85% b.w.
21. A method according to claim 18, 19 or 20, wherein the medicament is

administered orally.

22. A method according to claim 20, wherein the medicament is administered orally at a dosage from about 0.7g to about 1.5 g daily.
- 5 23. A method according to claim 22, wherein the EPA/DHA ration in the EPA+DHA mixture is about 0.9/1.5.
24. A method for preventing mortality in a patient who has survived a myocardial infarction, comprising administering to said patient a therapeutically effective amount of a medicament containing
- 10 essential fatty acids with a content in eicosapentaenoic acid ethyl ester (EPA) or in docosahexaenoic acid ethyl ester (DHA) greater than 25% b.w.
25. A method according to claim 24, wherein the content EPA or DHA is from about 60 to about 100% b.w.
- 15 26. A method according to claim 24 or 25, wherein the medicament is administered orally.
27. A method for preventing sudden death in a patient who is survivor of myocardial infarction, comprising administering to said patient a therapeutically effective amount of a medicament containing
- 20 essential fatty acids with a content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) greater than 25% b.w.
28. A method according to claim 27, wherein the content in EPA or DHA is from about 60 to about 100% b.w.
- 25 29. A method according to claim 27 or 28, wherein the medicament is administered orally.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/00957

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/23 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 760 081 A (A.LEAF, H.HALLAQ) 2 June 1998 (1998-06-02)</p> <p>claims 1,2,4 column 1, line 16-24 column 2, line 12-14 column 5, line 20-28 column 7, line 56-61 column 8, line 9-14</p> <p style="text-align: center;">--- -/--</p>	<p>1,2,8,9, 12,18, 24,27</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 June 2000

Date of mailing of the international search report

28/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Peeters, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/00957

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 753 703 A (C.CAVAZZA, M.CALVANI) 19 May 1998 (1998-05-19) claims 1,3,4,8 column 1, line 10-20 column 3, line 66 -column 4, line 2 column 4, line 16-19 ---	1,2,5,8, 9,11,12, 15,18, 21,24, 26,27,29
X	GB 2 218 984 A (RENAFIELD) 29 November 1989 (1989-11-29) claims 1,4,6-10,15-17 page 17, line 12-24 ---	1-5, 8-15, 18-21, 24-29
X	CHEMICAL ABSTRACTS, vol. 122, no. 8, 20 February 1995 (1995-02-20) Columbus, Ohio, US; abstract no. 89398, PAN YUZHEN, LIU RONGKUI, LIU ZHE: "soft capsules containing ethyl docosahexanoate and other ingredients for use as antithrombotic and antidementia agents" XP002139955 abstract & CN 1 082 909 A (PEOPLES REPUBLIC OF CHINA) 2 March 1994 (1994-03-02) ---	1,2,5,8, 9,11,12, 15,18, 21,24, 26,27,29
X	E.SWAHN E.A.: "Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients" CLINICAL DRUG INVESTIGATION, vol. 15, no. 6, 1998, pages 473-482, XP000914344 page 473 page 474 page 481, column 1 -----	1,2,5,8, 9,11-13, 15,18, 19,21, 24-29

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/00957

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5760081 A	02-06-1998	NONE	
US 5753703 A	19-05-1998	IT RM950835 A	23-06-1997
		CA 2191645 A	22-06-1997
		EP 0780124 A	25-06-1997
		JP 9176005 A	08-07-1997
GB 2218984 A	29-11-1989	AT 75502 T	15-05-1992
		CA 1334207 A	31-01-1995
		CN 1040050 A,B	28-02-1990
		DE 68901382 D	04-06-1992
		WO 8911521 A	30-11-1989
		EP 0409903 A	30-01-1991
		ES 2017268 A	16-01-1991
		GR 89100345 A	10-10-1991
		PT 90668 A,B	30-11-1989
CN 1082909 A	02-03-1994	NONE	